A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

• Status: Not yet recruiting
• Trial end date: 2021-07-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daewoong Pharmaceutical Co. LTD.

Criteria

Inclusion Criteria:

• Adults over the age of 19 as of the signed date in written consent

• Subjects in self-quarantine who contact from COVID-19 confirmed patient

• Subjects who have COVID-19 negative RT-PCR result

• Subjects with no symptoms of COVID-19

Exclusion Criteria:

• Subjects who cannot orally administer the investigational products

• Subjects who need administration of immunosuppressants

• Subjects who are allergic or sensitive to investigational products or its ingredients

• Subjects who have a history of drug and/or alcohol abuse within 12 months before screening

• Subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators